19 recruiting. 19 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Recruiting 19 |
| Phase 1 | 3 | Recruiting 3 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 33 | 2026-09-10 | 2026-09-09 |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer E-EDV-D682, EDV-GC, Gemcitabine - Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Engeneic Pty Limited | 144 | 2026-01-12 | 2026-02-27 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
| Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer Nimotuzumab, Toripalimab, Nab-paclitaxel - Head & Neck Cancer | Phase 2 | Recruiting | Tang-Du Hospital | 10 | 2025-11-15 | 2026-01-20 |
| Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles - Rectal Cancer Patients | Phase 2 | Recruiting | The Affiliated Hospital of Qingdao University | 35 | 2025-06-01 | 2026-03-06 |
| SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC SHR-A1811, Pertuzumab, Albumin-Paclitaxel - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | Recruiting | Henan Cancer Hospital | 180 | 2025-04-16 | 2025-06-23 |
| Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM BCMA CART - Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2025-03-03 | 2025-08-07 |
| Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy - Nasopharyngeal Neoplasms, PD-1 Inhibitor | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 208 | 2025-02-25 | 2025-07-01 |
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors Everolimus 5 MG - Neuroendocrine Tumors, Progression | Phase 2 | Recruiting | AC Camargo Cancer Center | 100 | 2024-04-24 | 2024-06-25 |
| Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer Dalcilib+letrozole+HP treatment group - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 71 | 2024-01-20 | 2024-12-17 |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2023-12-22 | 2025-12-04 |
| Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC Albumin paclitaxel+trastuzumab+pyrrolitinib, Docetaxel+Carboplatin+trastuzumab+Parstuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 610 | 2023-05-03 | 2025-03-07 |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET Lutathera - Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor | Phase 2 | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 146 | 2021-10-18 | 2026-06-04 |
| A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules Ablation therapy - Progression | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 120 | 2021-01-01 | 2021-05-27 |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II - Advanced Malignant Neoplasm, Breast Cancer | Phase 1 / Phase 2 | Recruiting | AtlasMedx, Incorporated | 122 | 2020-08-12 | 2025-05-01 |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer Nivolumab Injectable Product, Trans-arterial tirapazamine embolization - Hepatocellular Carcinoma, Gastric Cancer | Phase 2 | Recruiting | Teclison Ltd. | 54 | 2017-07-01 | 2026-04-16 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
Pathologic Complete Response (11) · Breast Neoplasms (6) · Pancreatic Neoplasms (3) · Neoplasms (2) · Neuroendocrine Tumors (2) · Ovarian Neoplasms (2) · Thrombocytopenia (2) · Adenoma, Islet Cell (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Carcinoid Tumor (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1)
Disease Attributes (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Neoplasms (15) · Neoplasms by Site (15) · Neoplasms by Histologic Type (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Breast Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Hematologic Diseases (4)
Carboplatin (4) · 130-nm albumin-bound paclitaxel (2) · Trastuzumab (2) · Tretinoin (2) · pertuzumab (2) · 4-hydroxy-N-desmethyltamoxifen (1) · ARX788 (1) · Ado-Trastuzumab Emtansine (1) · Capecitabine (1) · Chemoradiotherapy (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Docetaxel (1) · Doxorubicin (1) · Everolimus (1)
Henan Cancer Hospital (3) · Peking University People's Hospital (2) · AC Camargo Cancer Center (1) · AtlasMedx, Incorporated (1) · Engeneic Pty Limited (1) · French Innovative Leukemia Organisation (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · QuantumLeap Healthcare Collaborative (1) · Shanghai Zhongshan Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Tang-Du Hospital (1) · Teclison Ltd. (1) · The Affiliated Hospital of Qingdao University (1) · The First Affiliated Hospital of Xiamen University (1)
China (11) · United States (5) · France (2) · Brazil (1)
Zhenzhen Liu (3) · Xiaohui Zhang, MD (2) · Dehui Zou (1) · Deshayes Emmanuel, PHD (1) · Dr Himanshu Brahmbhatt, Ph.D (1) · Dr Jennifer MacDiarmid, Ph.D (1) · Dr Linda Y.Wu, MD (1) · Kimberly Johung, MD (1) · Laura Esserman, MD, MBA (1) · Nadine Abi-Jaoudeh, MD (1) · Pamela Munster, MD (1) · Zhao DaQing (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42523785, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224